Transforming the Treatment of Cancer & Inflammatory Diseases
Play Video
See our technology in action
Our Science
Our unique and proprietary epithelial stem cell cloning platform stemECHO provides unprecedented resolution at the cellular level and has led to the discovery of the underlying mechanism via pathogenic stem cells to treat certain forms of cancer and inflammatory diseases.
Tract has identified drugs that selectively target these pathogenic stem cells in inflammatory airway and intestinal diseases and certain forms of cancer.
Additionally, with our Tumor-activated peptide-drug-conjugate (PDC) technology, Tract has the potential to transform how cancer and inflammatory diseases are treated.
Learn More
Our Mission
Transform cancer treatment by developing drugs that eradicate cancer stem cells.
We aspire to enhance the lives of patients suffering from cancer, inflammation and other conditions by changing what’s possible in drug discovery.
Our Strategy
stemEcho is a proprietary technology that will allow us to clone epithelial stem cells millions of times while preserving their genetic integrity.
This is achieved by leveraging the fixed identity of transcription factors - key elements that regulate the function and identity of these stem cells. These transcription factors ensure the stem cells remain undifferentiated as they are replicated so that we grow pure colonies of them.
The result? A uniform population of cells, identical in every respect to the original.
One of the most promising applications is in the treatment of cancers and inflammatory diseases. By maintaining the genetic consistency of the cloned cells, researchers can study disease mechanisms with unprecedented precision. This opens the door to new diagnostic tools and therapies that target the root causes of these conditions.
stemECHO, our groundbreaking technology, allows us to clone and characterize the role of epithelial stem cells in the pathogenesis of inflammation and cancer. These insights will fundamentally change the treatment of certain forms of inflammatory diseases and cancers.
This technology could significantly enhance the future of treatment and prevention, making personalized medicine a standard of care. Tract Bio is pioneering the future of healthcare, transforming our knowledge of epithelial stem cell biology into life-changing therapies. The journey to a healthier world begins at the cellular level.
Pipeline
We have a robust development pipeline and expect to have an IND submitted in the next 24 months.
Oncology
Our Team
Our Scientific Founders are pioneers in stem cell biology and disease pathogenesis of epithelial tissue.
Their research has been widely published in peer reviewed top tier journals such as Cell and Nature.
Leadership &
Board of Directors
Richard Russell
Chief Executive Officer, Board Member
Joseph Suarez
CFO & COO
Robert Izard, J.D.
General Counsel, Board Chair
John Noseworthy, MD
Board Member
Ian Banwell
Board Member
Charlie Izard
Board Member
Mark J. Adler, MD
Board Member
Kristiina Vuori, MD
Board Member
Scientific Advisory Board
Jaffer A. Ajani, MD
Scientific Advisory Board
William Bachovchin, PhD
Scientific Advisory Board
Christopher Crum, MD
Scientific Advisory Board
Burton Dickey, MD
Scientific Advisory Board
Howard J. Huang
Scientific Advisory Board
Jeffrey Hyams, MD
Scientific Advisory Board
Ajay Sheshadri, MD
Scientific Advisory Board
Timothy C. Wang, MD
Scientific Advisory Board
Explore Our Video Library
News
Publications
See More
Interested in collaborating with us?
Join us in transforming medicine through revolutionary stem cell cloning and cutting-edge therapeutic breakthroughs.
